

January 22, 2026

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Press Release

Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the Press Release on Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2025.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

Rudalf Corriea
Company Secretary and Compliance Officer
Encl.: As above

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)

Corporate Office:

Technopolis Knowledge Park, A wing Office No. 401 to 407,
4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093

Registered Office:

Plot No 170-172, Chandramouli Industrial Estate
Mohol Bazarpeth, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com



Alivus Life Sciences reports strongest performance ever,

Delivering record revenues of Rs 6,729 Mn and highest ever EBITDA margins of 36.4%

Mumbai, January 22, 2026: Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited), a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, today announced its financial results for the quarter and nine months ended December 31, 2025.

For Q3FY26, Alivus registered a Revenue from operations of Rs. 6,729 Mn, highest ever quarterly revenues. This marks a growth of 14.4% QoQ and 4.8% YoY.

For 9MFY26, Revenue from operations was Rs. 18,627 Mn, a growth of 7.2% YoY.

For Q3FY26, EBITDA was at Rs. 2,452 Mn, a growth of 26.5% QoQ and 22.1% YoY. EBITDA margins were at record high at 36.4%, up 340 bps QoQ and 510 bps YoY. The performance was led by favourable product mix following a strong recovery in the CDMO business, increased contributions from new product launches and continued gains in operational efficiency.

For 9MFY26, EBITDA was at Rs. 6,204 Mn, a growth of 22.0% YoY. EBITDA margins were at 33.3%, up 400 bps YoY.

PAT for Q3FY26 stood at Rs. 1,503 Mn, a growth of 15.5% QoQ and 9.7% YoY. PAT margins were at 22.3%, up 100 bps YoY.

PAT for 9MFY26 stood at Rs. 4,019 Mn, a growth of 16.9% YoY. PAT margins were at 21.6%, up 180 bps YoY.

During 9MFY26, the company generated a strong free cash flow of Rs. 2,207 Mn leading to Cash and Cash Equivalents (including short term investments) of Rs. 7,330 Mn as of December 31, 2025.

Commenting on the company's performance Dr. Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited said, *"This quarter showed a clear improvement in our operating performance. The CDMO business recovered as expected, delivering the turnaround we had planned for in the second half of the year.*

We also saw robust growth in Non-GPL business especially across our key markets, including Europe, Japan, LATAM, ROW, and India, which collectively grew by 16% YoY during 9MFY26, in-line with our guidance. For full year, we expect Non-GPL to sustain its growth momentum, reinforcing our confidence in delivering high single-digit revenue growth for FY26. Driven by the strength of our core business and increased contributions from new product launches, we remain confident of sustaining margin expansion in the current year.

Our focus continues to be on building a sustainable, long-term business through high-quality offerings, innovation, and scalable operations."

Tushar Mistry, CFO, Alivus Life Sciences Limited said, *"Our focus on disciplined and sustainable growth translated into a strong performance this quarter, with revenues reaching Rs. 6,729 million. This was accompanied by an EBITDA margin of 36.4%, the highest we have achieved so far, reflecting the strength of our diversified product portfolio and continued improvements in operational efficiency.*

We also remain in a strong financial position, operating as a net debt-free company. Generated free cash flow of Rs. 2,207 million during 9MFY26, and cash and cash equivalents were at Rs. 7,330 million as of 31st December 2025."

PRESS RELEASE

For Immediate dissemination



Additional Highlights:

- DMF / CEP filings continue across major markets, taking the total cumulative filings to 595 as on December 31, 2025
- The HP API portfolio has 27 products in the active grid with nine products validated, seven products in advanced stages of development and 11 products under lab development stage

Capex Update:

- Solapur – Phase 1 and 1.1 construction work is in progress for 465 KL capacity
- To lead the future, we have acquired land in Taloja (Navi Mumbai) admeasuring 10,000 square meter to establish a state-of-the-art R&D centre, designed to advance complex chemistry and oncology research. The centre will focus on flow chemistry, complex products, particle engineering and green chemistry, strengthening our pipeline across key therapeutic areas.

About Alivus Life Sciences Ltd (ALIVUS)

Alivus Life Sciences Limited (Formerly Glenmark Life Sciences Limited) (BSE: 543322, NSE: ALIVUS), is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The company is increasingly providing CDMO services to a range of multinational and specialty pharmaceutical companies. It has a diversified portfolio of 176 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).

The company's four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe). Alivus Life Sciences is listed on BSE and NSE.

Learn more about Alivus Life Sciences Limited on <https://www.alivus.com>

For any further queries please contact:

Soumi Rao | General Manager – Corporate Communications

Email: Soumi.Rao@glenmarklifesciences.com

Mobile: 98701 96931

Ernst & Young LLP – Investor Relations

Diwakar Pingle

Email: Diwakar.Pingle@in.ey.com

Runjhun Jain

Email: Runjhun.Jain1@in.ey.com

Sneha Salian

Email: Sneha2.Salian@in.ey.com